ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2019
Primary malignant melanoma of esophagus: clinicopathologic characterization of 20 cases including molecular genetic profiling of 15 tumors.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Primary melanoma of the gastrointestinal tract.World journal of gastroenterology · 2026Review
- Case Report: Locally advanced primary esophageal melanoma with early brain metastasis.Frontiers in oncology · 2026Article
- Primary Malignant Melanoma of the Oesophagus Treated With Immunotherapy: A Case Report and Scoping Review of the Literature.Journal of gastrointestinal cancer · 2025Article
- Promising Treatment Strategy for Primary Malignant Melanoma of the Esophagus by Radical Esophagectomy and Nivolumab as Adjuvant Therapy: A Case Report.Surgical case reports · 2025Article
- A case of primary malignant melanoma of the esophagus.Radiology case reports · 2024Article
- Superficial Primary Malignant Melanoma of the Esophagus Detected and Treated at Stage 0.Internal medicine (Tokyo, Japan) · 2024Article
- A Rare and Rapidly Progressive Case of Primary Esophageal Malignant Melanoma in an Elderly Patient.Cureus · 2024Article
- Primary malignant melanoma of the oesophagus.United European gastroenterology journal · 2024Article
- Rare malignant neoplasm of the esophagus: current status and future perspectives.Japanese journal of clinical oncology · 2024Review
- Pathologic complete response to neoadjuvant imatinib of a gastric stromal tumor with concomitant mutations inClinical case reports · 2023Article
- Primary malignant melanoma of the esophagus: A case report.World journal of clinical cases · 2023Article
- Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy.Journal for immunotherapy of cancer · 2023Article
- Longitudinal genomic alternations and clonal dynamics analysis of primary malignant melanoma of the esophagus.Neoplasia (New York, N.Y.) · 2022Article
- The Thousand Faces of Malignant Melanoma: A Systematic Review of the Primary Malignant Melanoma of the Esophagus.Cancers · 2022Review
- Article
- Distribution and clinical role of KIT gene mutations in melanoma according to subtype: a study of 492 Spanish patients.European journal of dermatology : EJD · 2021Article
- Immunotherapy against esophageal primary amelanotic malignant melanoma relapse.Journal of surgical case reports · 2021Article
- Histopathological landscape of rare oesophageal neoplasms.World journal of gastroenterology · 2020Review
- Diagnosis and management of acute esophageal necrosis.Annals of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
Primary malignant melanoma of esophagus is very rare, and its clinicopathologic and genetic features have not been extensively investigated. In this study, 20 tumors from 14 male and 6 female patients (40-79 years old) were evaluated. Dysphagia, chest pain, and weight loss were frequent symptoms. Thirteen melanomas, including two with multiple lesions, involved the distal third of esophagus. The median tumor diameter was 6 cm. Epithelioid morphology, moderate atypia, and pigmentation were typical findings. None of the patients had melanoma elsewhere, and all tumors exhibited a junctional peri-epithelial component consistent with a primary lesion. The median mitotic activity was 11 per 10 high-power fields (range, 0-31). Nine patients died of tumor within 4-22 months, however, two showed long-term (96 and 104 months) survival. In 15 cases, tissue for further immunohistochemical and molecular studies were available. BRAF, KIT, and NRAS mutation status was assessed by Sanger sequencing in all 15 tumors. The next-generation sequencing of 50 or 409 genes was performed in five and three cases, respectively. IGF1R expression indicating activation of the IGF axis was seen in 82% (9/11) of tumors. However, no BRAF mutations were identified. In 33% (5/15) of tumors, NRAS mutations were detected. KIT expression was seen in 50% (7/14) of melanomas including single KIT mutant. Two of three tumors evaluated with 409 genes panel revealed multiple driver mutations indicating sub-clonal expansion, whereas a single mutation (TSC1 p.H371Q) was the sole change in the third case. SF3B1 p.K666T and p.R625C mutations were detected in two cases. However, no co-occurrence of SF3B1 and GNAQ or GNA11 mutations, seen in uveal melanoma, was detected. FBXW7 p.R465C and p.R479G mutations, linked to cancer progression, were found in two of eight tumors. In summary, esophageal melanoma mutation profile indicates complexity of molecular mechanisms underlying its pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.